Oxford GlycoSciences Plc Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Oxford GlycoSciences Plc

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Jongmans who wrote (58)	11/7/2000 2:21:20 PM
From: nigel bates	Read Replies (1) of 469

Seems as though there are benefits on both sides - "The new arrangement is more profitable for us going forward," Oxford CEO Michael Kranda told FTMarketWatch. Oxford Glycosciences specializes in sophisticated, large-scale computerized analysis and data-basing of proteins, which make up many vital components of the machinery of life. Incyte is one of the leading firms in genomics, the study of DNA sequences that form the blueprint for a cell's proteins. The two companies offer their combined services in the form of data bases and computerised analysis systems. The original deal was based on an annual payment by Incyte to Oxford of $5 million. Kranda said the revised deal maintained the $5 million floor and in addition made it possible for Oxford to take profits on its own work in the coming year. Cannot understand why they don't put this stuff in the PR if they are going to disclose it anyway... nig

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next